肝动脉注射治疗剂量^（131）Ⅰ－抗人肝癌McAb的RⅡ

CLINICAL STUDY OF RADIOIMMUNOIMAGIND WITH ^(131)I LABELLED ANTI-HUMAN PRIMARY HEPATIC CARCINOMA MONOCLONAL ANTIBODY

在动物实验基础上，以１３１Ⅰ标记抗人肝癌单克隆抗体ＨｅｐａｍａⅠ进行人体显像研究．单抗系小鼠ＩｇＧ１，裸鼠实验显示有良好的肿瘤定位效果。１８例原发性肝癌（ＰＨＣ）患者，以Ｓｅｌｄｉｎｓｅｒｓ法经肝固有动脉注入１３１Ⅰ－ＨｅｐａｍａⅠ，平均剂量为３５５ＭＢｑ／１．５ｍｇＩｇＧ１，术后行全身及肝区γ显像．测定全身重要脏器和癌区的放射性计数比值．结果：显像阳性率７７．７％，最佳时间为注入后９６小时，癌／肝比值在第４８小时为１．６５±０．３３，第９６小时为４．３８±１．４８，第２４０小时为２．２２±０．５７．本研究提示ＨｅｐａｍａⅠ在人体内与肝癌组织有较好亲和力．

Abstract Based on experimental animals,18 patients were administed through hepatic artery a mean dosage of 355 MBq / 1 .5mg of 131I-Hepama I which was a monoclonal antibody against PHC cells.Fourteen of 18 patients had positive scans(77.7%).The optimum imaging time was 96 hours after administration.Mean tumor/liver ratio was 4.28 ±1.48,and no toxicity was noted.